DepoVax™ Platform
The cornerstone of all vaccine development efforts at Immunovaccine is the company’s DepoVax™ vaccine adjuvanting platform. DepoVax is a patented vaccine delivery formulation that provides controlled and prolonged exposure of antigens plus adjuvant to the immune system. The result is a strong, specific and sustained immune response with the capability for single-dose effectiveness.The DepoVax platform possesses impressive fle…
The supplier does not provide quotations for this product through SelectScience. You can search for similar products in our Product Directory.
The cornerstone of all vaccine development efforts at Immunovaccine is the company’s DepoVax™ vaccine adjuvanting platform.
DepoVax is a patented vaccine delivery formulation that provides controlled and prolonged exposure of antigens plus adjuvant to the immune system. The result is a strong, specific and sustained immune response with the capability for single-dose effectiveness.
The DepoVax platform possesses impressive flexibility, allowing it to work with a broad range of target antigens in various therapeutic applications. The technology is also commercially scalable, with potential for years of stability and ease of use in the clinic.
To date, DepoVax has served as the basis for Immunovaccine’s two clinical-stage cancer immunotherapies, as well as a number of partnered vaccine programs spanning infectious diseases, bio-terrorism, addiction medicine and animal health. These collaborators include many leaders in their respective areas of focus including the National Institutes of Health and Zoetis (formerly Pfizer Animal Health).
Advantages:
- Humoral and/or cellular response possible
- Compatible with different antigens
- Stable formulation: long-term storage at ambient temperatures if necessary
- Easy to re-suspend and administer
